Acute mountain sickness (AMS) is a syndrome that can affect travelers who are not acclimatized and gain altitude too quickly, usually occurring above 2,500 m. (8,200 ft.) elevation.
In this report, the new CDC recommendations for the concomitant use of isoniazid (INH) and rifapentine (RPT) administered weekly for 12 weeks as directly observed therapy (DOT) are detailed.
In this issue: New treatment for TB; safety of dabigatran; quality of antidepressants; systolic hypertension treatment; and FDA actions.
Investigators from The Netherlands conducted a prospective study to assess whether short-term travelers on immunosuppressive agents (ISA) or those with inflammatory bowel disease (IBD) had increased risk of infectious diseases compared to matched controls.
